Loading stock…

Raia Drogasil S.A. (RADL3) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

RADL3Raia Drogasil S.A.

Revenue FY25$8.1B

GROWTH RATING↗

STRONG73 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+14%8

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+9%7

Revenue, next 5Y, CAGR+10%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+26%8

EPS growth, FY27E+25%8

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 73% of companies worldwide.

Revenue grew 14%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 9%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 10%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 25%/yr vs revenue 9%/yr), so margins should widen.

WATCH

Revenue grew 14%/yr over the last 3 years; forecasts see it cooling to 9%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

RADL3Raia Drogasil S.A.

Total return Current27.4%

Price return Current17.0%

MOMENTUM RATING↗

AVERAGE66 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+11%10

3-month return+20%10

YTD return-6%4

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return+19%7

3-year return-16%2

5-year return+7%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+11%) and over three months (+20%).

WATCH

It's up 19% over the past year, but 23% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-16% over three years and +7.1% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Raia Drogasil. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RADL3Raia Drogasil S.A.

Revenue FY25$8.1B

GROWTH RATING↗

STRONG73 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+14%8

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+9%7

Revenue, next 5Y, CAGR+10%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+26%8

EPS growth, FY27E+25%8

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 73% of companies worldwide.

Revenue grew 14%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 9%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 10%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 25%/yr vs revenue 9%/yr), so margins should widen.

WATCH

Revenue grew 14%/yr over the last 3 years; forecasts see it cooling to 9%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

RADL3Raia Drogasil S.A.

Total return Current27.4%

Price return Current17.0%

MOMENTUM RATING↗

AVERAGE66 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+11%10

3-month return+20%10

YTD return-6%4

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return+19%7

3-year return-16%2

5-year return+7%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+11%) and over three months (+20%).

WATCH

It's up 19% over the past year, but 23% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level so far this year (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-16% over three years and +7.1% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Raia Drogasil. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Raia Drogasil S.A.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Raia Drogasil. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Raia Drogasil. Get the full investment case.

Premium